OncLive TV

Rupert Bartsch, MD, discusses findings from the final analysis of the phase 2 TUXEDO-1 trial of trastuzumab deruxtecan in patients with HER2-positive breast cancer with active brain metastases.

Sikander Ailawadhi, MD, oncologist, Department of Hematology, CAR T-Cell Therapy Program, Mayo Clinic, discusses how the investigational agent iopofosine I-131 may address unmet needs for patients with Waldenström macroglobulinemia.

Aiwu Ruth He, MD, PhD, discusses the evaluation of camrelizumab plus rivoceranib in unresectable hepatocellular carcinoma.

Andrea Necchi, MD, discusses results from the phase 2b SunRISe-1 trial of TAR-200 in patients with Bacillus Calmette-Guérin (BCG)–unresponsive, high-risk, non–muscle-invasive bladder cancer.

Lori A. Leslie, MD, discusses the significance of the FDA approval of pirtobrutinib for patients with pretreated chronic lymphocytic leukemia or small lymphocytic lymphoma.

Brian T. Hill, MD, PhD, discusses the final results from a phase 1/2 trial of carfilzomib given with R-CHOP in the frontline setting for patients with non-germinal center diffuse large B-cell lymphoma.

David A. Sallman, MD, discusses the rationale for conducting a phase 2, multi-institutional, investigator-initiated clinical trial on the use of fedratinib in patients with myelodysplastic syndromes/myeloproliferative neoplasm overlap syndromes and chronic neutrophilic leukemia.

Aaron Gerds, MD, discusses the importance of evaluating the efficacy and safety of selinexor in patients with JAK inhibitor–naive myelofibrosis, as assessed in the phase 1/3 XPORT-MF-034 trial.

Sarah Sammons, MD, discusses the goals of treating patients with breast cancer who present with active vs stable brain metastasis.

Kathryn A. Gold, MD, discusses the benefit of targeted therapies in patients with mutated lung cancers.

Richard Kim, MD, discusses a case study of a patient who presented with hepatocellular carcinoma, detailing the steps that were taken upon diagnosis.

Debra L. Richardson, MD, FACS, FACOG, discusses the impact of selinexor’s mechanism of action on the agent’s clinical efficacy in patients with TP53 wild-type advanced or recurrent endometrial cancer.

Tatyana Feldman, MD, discusses updated safety and efficacy data from the phase 1/2 TRANSCEND CLL 004 trial in patients with relapsed/refractory chronic lymphocytic leukemia or small lymphocytic lymphoma.

Lori A. Leslie, MD, discusses the efficacy and safety of second-line axicabtagene ciloleucel in elderly patients with high-risk, relapsed/refractory large B-cell lymphoma.

Komal Jhaveri, MD, FACP, discusses the rationale for investigating lasofoxifene alongside abemaciclib in ESR1-mutated estrogen receptor–positive, HER2-negative metastatic breast cancer.

Laura A. Huppert, MD, discusses the impact of sequential treatment with fam-trastuzumab deruxtecan-nxki and sacituzumab govitecan-hziy on outcomes in patients with HER2-low metastatic breast cancer, according to findings from a retrospective analysis.

Brian I. Rini, MD, FASCO, discusses the significance of the FDA approval of belzutifan for the treatment of patients with advanced renal cell carcinoma

Sandip P. Patel, MD, discusses the utilization of sacituzumab govitecan in non–small cell lung cancer, highlighting trials in which the TROP2-directed antibody-drug conjugate is being evaluated in this patient population.

Naoki Niikura, MD, PhD, discusses the impact of treatment with trastuzumab deruxtecan in patients with HER2-positive breast cancer with brain metastases and/or leptomeningeal disease, as evaluated in the real-world ROSET-BM study in Japan.

Marta Vaz Batista, MD, discusses the efficacy of trastuzumab deruxtecan in patients with HER2-positive or HER2-low advanced breast cancer and pathologically confirmed leptomeningeal carcinomatosis, as evaluated in cohort 5 of the phase 2 DEBBRAH study.

Adam M. Brufsky, MD, PhD, FACP, discusses the significance of the FDA approval of capivasertib in combination with fulvestrant for patients with hormone receptor-positive, HER2-negative, locally advanced or metastatic breast cancer harboring 1 or more PIK3CA, AKT1, or PTEN alterations.

Kai-Keen Shiu, MD, discusses the significance of the FDA approval of pembrolizumab in combination with fluoropyrimidine- and platinum-containing chemotherapy as a first-line treatment in patients with locally advanced, unresectable or metastatic, HER2-negative gastric or gastroesophageal junction adenocarcinoma.

Jorge J. Castillo, MD, discusses the ongoing investigation into potential treatment options for patients with Waldenström macroglobulinemia, including iopofosine I-131.

Patrick Y. Wen, MD, discusses the evaluation of vorasidenib in IDH1- and IDH2-mutated low-grade glioma, as evaluated in the phase 3 INDIGO trial.

Lajos Pusztai, MD, DPhil, discusses the phase 2 DARE trial evaluating circulating tumor DNA-guided second-line adjuvant therapy for patients with high-risk, stage II-III, estrogen receptor-positive, HER2-negative breast cancer, highlighting the importance of researching ctDNA utility in this patient population.

Akshat Jain, MBBS, discusses the importance of novel therapies in the treatment of pediatric patients with beleeding disorders.

Ajai Chari, MD, discusses the efficacy of treating patients with less frequent or lower intensity dosing of talquetamab in patients with relapsed/refractory multiple myeloma, as evaluated in the phase 1/2 MonumenTAL-1 study.

Jennifer A Woyach, MD, discusses the efficacy of pirtobrutinib in patients with chronic lymphocytic leukemia or small lymphocytic lymphoma who progressed on treatment with a covalent BTK inhibitor, including subgroups with or without previous exposure to a BCL2 inhibitor.

Aditya Bardia, MD, MPH, discusses key efficacy results from the phase 3 TROPION-Breast01 trial of datopotamab deruxtecan in hormone receptor–positive, HER2-negative breast cancer.

Sara M. Tolaney, MD, MPH, discusses the real-world efficacy of fam-trastuzumab deruxtecan in patients with HER2-positive or HER2-low metastatic breast cancer, including patients who experienced changes in HER2 status during the treatment course.